Molecular dissection of Janus kinases as drug targets for inflammatory diseases [PDF]
Frontiers in Immunology, 2022 The Janus kinase (JAK) family enzymes are non-receptor tyrosine kinases that phosphorylate cytokine receptors and signal transducer and activator of transcription (STAT) proteins in the JAK-STAT signaling pathway.
Sunghark Kwon
doaj +2 more sources
Targeting of Janus Kinases Limits Pro-Inflammatory but Also Immunosuppressive Circuits in the Crosstalk between Synovial Fibroblasts and Lymphocytes [PDF]
Biomedicines, 2021 Crosstalk between synovial fibroblasts (SF) and immune cells plays a central role in the development of rheumatoid arthritis (RA). Janus kinase inhibitors (JAKi) have proven efficacy in the treatment of RA, although clinical responses are heterogeneous ...
Nina Yao +6 more
doaj +2 more sources
In Silico and In Vitro Study of Janus Kinases Inhibitors from Naphthoquinones [PDF]
Molecules, 2023 Janus kinases (JAKs) are involved in numerous cellular signaling processes related to immune cell functions. JAK2 and JAK3 are associated with the pathogenesis of leukemia and common lymphoid-derived illnesses.
Kamonpan Sanachai +8 more
doaj +2 more sources
Baricitinib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Janus Kinases [PDF]
Pharmaceuticals, 2019 In 2018, Baricitinib was approved by the Food and Drig Administration (FDA) for the treatment of rheumatoid arthritis. Baricitinib exerts its action by targeting Janus kinases (JAK).
Annie Mayence +1 more
doaj +2 more sources
Janus kinases inhibitors for coronavirus disease-2019: A pairwise and Bayesian network meta-analysis [PDF]
Frontiers in Medicine, 2022 BackgroundJAK (Janus kinases) inhibitors have been proposed as a promising treatment option for the coronavirus disease-2019 (COVID-19). However, the benefits of JAK inhibitors and the optimum thereof for COVID-19 have not been adequately defined ...
Jianyi Niu +18 more
doaj +2 more sources
Revisiting Janus kinases as molecular drug targets for rheumatic diseases [PDF]
Frontiers in MedicineJanus kinase (JAK) family members, as upstream regulators, phosphorylate not only themselves but also cytokine receptors and signal transducer and activator of transcription (STAT) proteins in the JAK-STAT signaling pathway.
Sunghark Kwon, Sunghark Kwon
doaj +2 more sources
Parthenolide Inhibits STAT3 Signaling by Covalently Targeting Janus Kinases [PDF]
Molecules, 2018 Aberrant activations of the STAT3 (signal transducer and activator of transcription 3) signaling pathway are associated with cancer and inflammatory diseases.
Man Liu +5 more
doaj +2 more sources
Janus kinase inhibitors - their current applications and future prospects [PDF]
Farmacja Polska, 2022 Janus kinase inhibitors are a group of drugs that provide an alternative to conventional therapy for numerous diseases. The most studied drug of this group is tofacitinib.
Natalia Wierzbowska +4 more
doaj +1 more source
Partial repigmentation of vitiligo with tofacitinib, without exposure to ultraviolet radiation, [PDF]
Anais Brasileiros de Dermatologia, 2020 Vitiligo is a disease that causes macules and achromic and/or hypochromic patches, which can affect from small areas to the entire tegument. Treatment options are few and are generally ineffective.
Melpone Komnitski +3 more
doaj +1 more source
Insights into the Binding Recognition and Susceptibility of Tofacitinib toward Janus Kinases [PDF]
ACS Omega, 2020 Kamonpan Sanachai +5 more
doaj +2 more sources